BioCentury | May 11, 2018
Financial News

Neurana closes $60M series A

...relaxer tolperisone from Sanochemia Pharmazeutika AG (Xetra:SAC). The drug is marketed in Europe and Asia. Tolperisone...
...Longitude's Josh Richardson joined Neurana's board. Neurana Pharmaceuticals Inc., San Diego, Calif. Mark Zipkin Agileo, Viveo, tolperisone (AV650) H.I.G...
BioCentury | May 7, 2018
Financial News

Neurana closes $60M series A

...relaxer tolperisone from Sanochemia Pharmazeutika AG (Xetra:SAC). The drug is marketed in Europe and Asia. Tolperisone...
...Dan Becker, H.I.G.'s Alex Zisson and Longitude's Josh Richardson joined Neurana's board. Mark Zipkin Agileo, Viveo, tolperisone (AV650) H.I.G...
BioCentury | Oct 8, 2012
Company News

Katama Pharmaceuticals, Sanochemia deal

...Sanochemia granted newco Katama exclusive rights in North America to develop and commercialize spasticity product tolperisone...
...Sanochemia, which will manufacture tolperisone for Katama, is eligible for milestones, plus royalties. Sanochemia markets tolperisone...
BioCentury | Oct 6, 2012
Company News

Newco Katama in deal for Sanochemia's tolperisone

...Inc. (San Diego, Calif.) exclusive rights in North America to develop and commercialize spasticity product tolperisone...
...Sanochemia, which will manufacture tolperisone for Katama, is eligible for milestones, plus royalties. Sanochemia markets tolperisone...
BioCentury | Nov 2, 2009
Clinical News

Myderison tolperisone regulatory update

...states the agency concluded that the benefits did not outweigh the risks for Meditop's Myderison tolperisone...
...Republic, Germany, Lithuania, Poland and Slovakia. Meditop Pharmaceutical Co. Ltd. , Pilisborosjeno, Hungary Product: Myderison tolperisone...
BioCentury | Jan 19, 2009
Finance

Ebb & Flow

...Lampert wrote to Avigen shareholders. Deal in the wings On Oct. 21, Avigen's tolperisone ( AV650...
BioCentury | Jan 5, 2009
Company News

Avigen, Baxter, MediciNova deal

...October and returned to Sanochemia Pharmazeutika AG (Xetra:SAC, Vienna, Austria) its rights to tolperisone ( AV650...
BioCentury | Jan 5, 2009
Finance

4Q approvals

...clinical trials and product manufactured on a commercial scale Avigen (NASDAQ:AVGN) Discontinues development of tolperisone (AV650...
BioCentury | Dec 24, 2008
Company News

MediciNova bids for Avigen

...The company restructured in October and returned to Sanochemia (Xetra:SAC) its rights to tolperisone ( AV650...
BioCentury | Dec 15, 2008
Finance

Ebb & Flow

...per share cash value. On Oct. 21, the company had announced that its tolperisone ( AV650...
...of his current stake in the past seven weeks. In the run up to the AV650...
Items per page:
1 - 10 of 28